Newly diagnosed patients with myeloma who are about to start treatment may benefit from a fixed course of prophylactic antibiotics to prevent Pneumocystis pneumonia, new research suggests. The double-blind phase III randomised TEAMM trial of almost 1,000 newly diagnosed patients showed that a 12-week course of levofloxacin (500mg daily) during myeloma treatment reduced the incidence...Continue Reading